CRISPR therapy EBT-101 targeted HIV DNA inside living humans for the first time, showing strong safety results but failing to prevent viral rebound after ART stopped.

Figure 2 from the PURPOSE-1 trial changed the world. Between gray and red bars representing the study’s background HIV incidence and the arms randomized to receive oral pre-exposure prophylaxis (PrEP) ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...

By Emma Farge GENEVA, July 27 (Reuters) - The world risks a resurgence of the HIV epidemic after global funding fell by ...

Q2 2026 earnings call recap: raised HIV/PrEP outlook, Yeztugo momentum, Veklury reset, and deal-driven EPS hit.

Researchers at the UC Davis School of Medicine have identified a naturally occurring metabolite that repairs gut damage ...

Cambodia is the first country in the Asia–Pacific to reach the 95–95–95 targets. There is hope that other countries might ...

Aging with HIV comes with an increased risk of other health problems. Failing to get adequate care could undermine fighting the virus. (Story aired on Weekend Edition Saturday on June 15, 2024.) ...

Among healthcare providers, 89% (n=16/18) reported a positive overall opinion of administering CAB LA for PrEP in their practice. Prescribers cited benefits of regular injection visits, including ...

For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford ...

SEATTLE – October 27, 2025 –Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...